340B reduces what a covered entity pays for a drug; it does not change the billed charge. What it does change is identification — Medicaid duplicate discount rules and payer carve-out policies require claims to indicate whether the drug came from 340B inventory, and getting that wrong is a compliance matter.
340B is frequently discussed as a pricing program, which is accurate and incomplete. For a billing operation it is mostly an identification and inventory problem.
What the program does
It lets eligible covered entities purchase outpatient drugs at reduced prices. The saving sits on the acquisition side. What you bill the payer does not change because the drug was purchased under 340B.
That gap between acquisition and reimbursement is the program’s intended benefit, and it is exactly why the rules around identification are strict.
Duplicate discounts are the core restriction
A manufacturer should not have to give both a 340B discount and a Medicaid rebate on the same unit. Preventing that requires states and payers to know which dispensed units came from 340B stock.
Hence modifiers, hence claim identifiers, hence a real requirement that your billing system knows which inventory a dose came from.
Carve-in or carve-out
A covered entity decides whether to use 340B drugs for Medicaid patients and registers that decision. Carving in means those claims need identifying; carving out means 340B stock must not be used for them at all.
Either way the decision has to be reflected in dispensing practice, not just on a form.
Payer policies vary
Commercial payers increasingly have their own 340B policies, some requiring identification and some adjusting reimbursement. Medicaid managed care plans add their own on top of the state program.
There is no single modifier or rule that satisfies everyone, which makes a per-payer reference necessary rather than optional.
Inventory is the compliance record
The audit question is whether drugs purchased at 340B prices were dispensed to eligible patients at eligible sites. Answering it requires records tying purchases to dispensing.
Practices that run mixed inventory without tracking origin cannot answer it, and inability to answer is itself the finding.
Contract pharmacy adds complexity
Where dispensing happens through a contract pharmacy, the tracking spans two organizations and manufacturers have restricted these arrangements in various ways.
That landscape has moved repeatedly, so a policy understood two years ago should be re-checked rather than assumed.
What to confirm internally
Your carve status, which payers require identification and how, whether your system flags 340B inventory at the claim line, and whether purchase and dispensing records reconcile.
Those four are what an audit examines and what a billing error in this area turns on.
Common questions
- Does 340B change what I bill?
- Not the charge itself. It changes acquisition cost, and it adds identification requirements so payers and states can apply duplicate discount and carve-out rules.
- What is a duplicate discount?
- When a manufacturer gives both a 340B discount and a Medicaid rebate on the same unit. Preventing it is why 340B claims must be identifiable.
- Which modifiers are used?
- Payers and Medicaid programs specify their own — commonly a modifier indicating a 340B-acquired drug. Requirements differ by payer and by state, so there is no single answer.
- What is a carve-in or carve-out?
- Whether a covered entity uses 340B drugs for Medicaid patients. The decision is registered and it determines how those claims must be handled.
- Who audits this?
- HRSA audits covered entities and manufacturers can request audits. Inventory records that tie purchases to eligible patients are what the audit examines.
Denials Piling Up?
We handle the revenue cycle end to end — coding by certified coders, claim submission, denial management and appeals, and A/R follow-up, with six reported numbers every month.